These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2783 related items for PubMed ID: 23662321

  • 1. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [Abstract] [Full Text] [Related]

  • 2. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [Abstract] [Full Text] [Related]

  • 3. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L, Jones LE.
    Cochrane Database Syst Rev; 2017 Feb 09; 2(2):CD001100. PubMed ID: 28182249
    [Abstract] [Full Text] [Related]

  • 4. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG.
    Lancet Haematol; 2016 Jan 09; 3(1):e12-21. PubMed ID: 26765643
    [Abstract] [Full Text] [Related]

  • 5. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L, Strachan J.
    Cochrane Database Syst Rev; 2017 Feb 14; 2(2):CD006771. PubMed ID: 28195640
    [Abstract] [Full Text] [Related]

  • 6. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K, Enoxaparin Clinical Trial Group.
    Ann Intern Med; 2001 Feb 06; 134(3):191-202. PubMed ID: 11177331
    [Abstract] [Full Text] [Related]

  • 7. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.
    Quinlan DJ, McQuillan A, Eikelboom JW.
    Ann Intern Med; 2004 Feb 03; 140(3):175-83. PubMed ID: 14757615
    [Abstract] [Full Text] [Related]

  • 8. Pentasaccharides for the treatment of deep vein thrombosis.
    Brandao GM, Junqueira DR, Rollo HA, Sobreira ML.
    Cochrane Database Syst Rev; 2017 Dec 02; 12(12):CD011782. PubMed ID: 29199766
    [Abstract] [Full Text] [Related]

  • 9. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG.
    Eur J Med Res; 2004 Apr 30; 9(4):225-39. PubMed ID: 15210403
    [Abstract] [Full Text] [Related]

  • 10. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S, Kluger J, Makanji S, Ashaye A, White CM.
    Pharmacotherapy; 2012 Sep 30; 32(9):799-808. PubMed ID: 22744711
    [Abstract] [Full Text] [Related]

  • 11. Home versus in-patient treatment for deep vein thrombosis.
    Othieno R, Okpo E, Forster R.
    Cochrane Database Syst Rev; 2018 Jan 09; 1(1):CD003076. PubMed ID: 29315455
    [Abstract] [Full Text] [Related]

  • 12. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
    Akl EA, Kahale L, Sperati F, Neumann I, Labedi N, Terrenato I, Barba M, Sempos EV, Muti P, Cook D, Schünemann H.
    Cochrane Database Syst Rev; 2014 Jun 26; (6):CD009447. PubMed ID: 24966161
    [Abstract] [Full Text] [Related]

  • 13. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
    van Rein N, Biedermann JS, van der Meer FJM, Cannegieter SC, Wiersma N, Vermaas HW, Reitsma PH, Kruip MJHA, Lijfering WM.
    J Thromb Haemost; 2017 Jul 26; 15(7):1386-1391. PubMed ID: 28440008
    [Abstract] [Full Text] [Related]

  • 14. [Evidence-based guidelines for prevention and therapy of venous thromboembolism].
    Falciani M, Dilaghi B, Conti AA, Caciolli S, Gensini GF.
    Minerva Cardioangiol; 2000 Dec 26; 48(12 Suppl 1):27-35. PubMed ID: 11253337
    [Abstract] [Full Text] [Related]

  • 15. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
    Junqueira DR, Zorzela LM, Perini E.
    Cochrane Database Syst Rev; 2017 Apr 21; 4(4):CD007557. PubMed ID: 28431186
    [Abstract] [Full Text] [Related]

  • 16. [Anticoagulation in patients with venous thromboembolism].
    Rüfer A, Wuillemin WA.
    Ther Umsch; 2003 Jan 21; 60(1):43-7. PubMed ID: 12638478
    [Abstract] [Full Text] [Related]

  • 17. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.
    Morris TA, Castrejon S, Devendra G, Gamst AC.
    Chest; 2007 Oct 21; 132(4):1131-9. PubMed ID: 17646239
    [Abstract] [Full Text] [Related]

  • 18. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Büller HR.
    Thromb Haemost; 2000 May 21; 83(5):652-6. PubMed ID: 10823256
    [Abstract] [Full Text] [Related]

  • 19. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ.
    Chest; 2008 Jun 21; 133(6 Suppl):454S-545S. PubMed ID: 18574272
    [Abstract] [Full Text] [Related]

  • 20. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J, Riess H, Büller HR, Brom J, Weidinger G, Huisman MV.
    Haematologica; 2003 Oct 21; 88(10):1157-62. PubMed ID: 14555312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 140.